Document Type : Case Report
Department of Flow Cytometry, Takhte Tavous Pathobiology Laboratory, Tehran, Iran Department of Clinical Laboratory Sciences, School of Allied Medical Sciences, Guilan University of Medical Sciences, Langeroud, Iran
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Dentistery student, Islamic Azad University, Tehran dental blanch
Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran
Applied Microbiology Research Center, Systems Biology and Prognosis Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Department of Flow Cytometry, Rasad Pathobiology and Genetic Laboratory, Tehran, IranTehran, Iran
Background: Helicobacter pylori is a gram-negative spirochete that usually affects the gastric mucosa and has a prevalence of more than 50% of people worldwide. It has been revealed that Helicobacter pylori infection is not only associated with chronic gastritis and peptic ulcers, but also with some hematologic disorders such as immune thrombocytopenia, iron deficiency anemia and gastric mucosa-associated lymphoid tissue lymphoma. Immune thrombocytopenia is an acquired autoimmune disorder with low platelet count due to devastation of autoantibody-coated platelets.
Case report: In the present study, it was reported an Iranian patient with severe immune thrombocytopenia (platelet count 1×109/L) and Helicobacter pylori infection who achieved a long lasting platelet recovery after Helicobacter pylori eradication therapy. The patient was followed up for two years and no failure in platelet response was observed.
Conclusion: Accordingly, Helicobacter pylori treatment is not only useful in immune thrombocytopenia patients with mild and moderate thrombocytopenia but also may be beneficial in severe cases of immune thrombocytopenia.